PC, Baker AJ. The ␣ 1A-adrenergic receptor subtype mediates increased contraction of failing right ventricular myocardium. Am J Physiol Heart Circ Physiol 309: H888 -H896, 2015. First published June 26, 2015 doi:10.1152/ajpheart.00042.2015.-Dysfunction of the right ventricle (RV) is closely related to prognosis for patients with RV failure. Therefore, strategies to improve failing RV function are significant. In a mouse RV failure model, we previously reported that ␣ 1-adrenergic receptor (␣1-AR) inotropic responses are increased. The present study determined the roles of both predominant cardiac ␣ 1-AR subtypes (␣1A and ␣1B) in upregulated inotropy in failing RV. We used the mouse model of bleomycininduced pulmonary fibrosis, pulmonary hypertension, and RV failure. We assessed the myocardial contractile response in vitro to stimulation of the ␣ 1A-subtype (using ␣1A-subtype-selective agonist A61603) and ␣1B-subtype [using ␣1A-subtype knockout mice and nonsubtype selective ␣ 1-AR agonist phenylephrine (PE)]. In wildtype nonfailing RV, a negative inotropic effect of ␣ 1-AR stimulation with PE (force decreased Ϸ50%) was switched to a positive inotropic effect (PIE) with bleomycin-induced RV injury. Upregulated inotropy in failing RV occurred with ␣ 1A-subtype stimulation (force increased Ϸ200%), but not with ␣1B-subtype stimulation (force decreased Ϸ50%). Upregulated inotropy mediated by the ␣ 1A-subtype involved increased activator Ca 2ϩ transients and increased phosphorylation of myosin regulatory light chain (a mediator of increased myofilament Ca 2ϩ sensitivity). In failing RV, the PIE elicited by the ␣1A-subtype was appreciably less when the ␣ 1A-subtype was stimulated in combination with the ␣1B-subtype, suggesting functional antagonism between ␣ 1A-and ␣1B-subtypes. In conclusion, upregulation of ␣ 1-AR inotropy in failing RV myocardium requires the ␣1A-subtype and is opposed by the ␣ 1B-subtype. The ␣1A subtype might be a therapeutic target to improve the function of the failing RV. FAILURE OF THE RIGHT VENTRICLE (RV) is a serious and common clinical problem (15, 24); nevertheless, RV failure remains relatively understudied and poorly understood (37). RV dysfunction is a predictor of survival for patients with moderate or advanced heart failure (7, 9) and is strongly related to the prognosis of heart failure patients with pulmonary hypertension (14). Therefore, strategies to improve RV function may be beneficial for improving the survival and functional state of patients with severe RV failure.
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NEW & NOTEWORTHY
For failing right ventricle (RV) myocardium, ␣1-adrenergic receptor (␣ inotropic responses were increased. Of the two predominant cardiac ␣1-AR subtypes (␣1A and ␣1B), increased ␣1-AR inotropy for failing RV myocardium required the ␣1A-subtype and was opposed by the ␣1B-subtype. The ␣1A-subtype might be a therapeutic target to improve the function of the failing RV.
FAILURE OF THE RIGHT VENTRICLE (RV) is a serious and common clinical problem (15, 24) ; nevertheless, RV failure remains relatively understudied and poorly understood (37) . RV dysfunction is a predictor of survival for patients with moderate or advanced heart failure (7, 9) and is strongly related to the prognosis of heart failure patients with pulmonary hypertension (14) . Therefore, strategies to improve RV function may be beneficial for improving the survival and functional state of patients with severe RV failure.
Recent studies suggest that in heart failure, a higher level of ␣ 1 -adrenergic receptor (AR) activation is beneficial (3, 20, 29) . In heart failure ␤-ARs are markedly downregulated; in contrast, ␣ 1 -AR levels are not decreased (4) . Consequently, ␣ 1 -ARs, which represent Ϸ10% of all ARs in nonfailing hearts, are increased to Ϸ25% of ARs in heart failure (29) . Thus ␣ 1 -ARs may play a relatively greater role in heart failure. Consistent with this, in myocardium isolated from failing human hearts, ␣ 1 -AR mediated inotropy was upregulated and equaled ␤-AR mediated inotropy (34) . Moreover, we reported that in a mouse model of RV failure induced secondary to LV failure, the RV myocardial inotropic response to ␣ 1 -ARs was upregulated (38) .
There are two predominant ␣ 1 -AR subtypes on cardiac myocytes (␣ 1 A and ␣ 1 B). The goal of this study was to determine the roles of both ␣ 1 -AR subtypes in upregulation of ␣1-AR inotropic responses in the failing RV. We used the RV-specific mouse heart failure model of bleomycin-induced pulmonary fibrosis, pulmonary hypertension, and RV failure (17) . We found that upregulated ␣ 1 -AR inotropy in the falling RV is associated exclusively with the ␣ 1 A-subtype and involves increased Ca 2ϩ transients and increased phosphorylation of cardiac myosin regulatory light chain. In contrast, inotropic responses mediated by the ␣ 1 B-subtype were not changed compared with nonfailing RV. Therefore, this study demonstrates that the ␣ 1 A-subtype, but not the ␣ 1 B-subtype, plays a role in augmenting contraction in RV failure and suggests that the ␣ 1 A-subtype might be a therapeutic target for improving the function of the failing RV.
METHODS
nary hypertension, and RV failure (17) . In anesthetized mice, a light-guide positioned close to the chest was used to visualize the trachea and to position a catheter to deliver a solution of bleomycin or saline into the trachea. Bleomycin (Sigma-Aldrich, St. Louis, MO) was solubilized in sterile normal saline. Most animals were given a single instillation of 0.075 U of bleomycin in 100 l saline or saline alone, and animals were harvested after 14 -30 days. A subset of animals (reported in Fig. 3A) were studied Ͻ2 wk after bleomycin instillation, but the data from this subset were not pooled with all other data obtained Ͼ2 wk after bleomycin instillation. Where indicated in the results, a few animals received a lower dose of bleomycin (0.04 U) repeated every 2 wk (up to 8 instillations) (8) . The repetitive instillation protocol was suggested to be a better model for idiopathic pulmonary fibrosis. In the present study, similar results were obtained using either protocol.
In vivo hemodynamics. Echocardiography was performed on conscious, gently restrained mice using an Acuson S2000 (Siemens) with a 5-to 14-MHz multi-dimension matrix transducer. RV and LV dimensions were measured using two-dimensional-guided M-mode, acquired from five consecutive cardiac cycles in the long axis view. Measurements were taken at midway along the heart. Fractional shortening for each chamber was calculated from the diastolic minus systolic chamber dimension expressed as a percentage of the diastolic dimension. The echocardiographer was blinded to the treatments of all mice.
RV trabecula preparation and measurement of calcium transients. Mice were anesthetized with 100 mg/kg ip pentobarbital sodium and heparinized (100 U). Hearts were removed and immediately immersed in ice-cold arrest solution containing (in mM) 120 NaCl, 30 KCl, and 0.1 CaCl 2 and then perfused through the aorta with a modified Krebs-Henseleit solution containing (in mM) 137 NaCl, 10 KCl, 1.2 MgSO4, 1.2 NaH2PO4, 10 glucose, 20 NaHCO3, 0.2 CaCl2, and 30 2,3,-butanedione monoxime. The perfusate was oxygenated with 95% O2-5% CO2 to give a pH of 7.4 at 22°C. The RV free-wall was removed, and a trabecula that was free-running between the RV wall and tricuspid valve was dissected.
Trabeculae were placed in a muscle chamber (3 ϫ 3 ϫ 15 mm) and mounted on stainless steel pins with the valvular end attached to a micromanipulator and the ventricular end attached to a force transducer (AE-801; Kronex, Oakland, CA). Sarcomeres were observed using a 40ϫ objective, and sarcomere length was assessed using a video-based system (Model 900B; Aurora Scientific, Ontario, Canada). Diastolic sarcomere length was set to 2.1 m. Trabeculae were equilibrated for 1 h in Krebs-Henseleit solution (5 ml/min) as described above but with 5 mM KCl and no 2,3-butanedione monoxime. The calcium level of the solution was gradually increased up to 1.1-1.5 mM, and trabeculae stimulated to contract at a pacing frequency of 0.5 Hz using platinum wire electrodes at maximal voltage.
To measure Ca 2ϩ transients, trabeculae were loaded with fura-2-AM by superfusion for 1.5 h with a Krebs-Henseleit solution containing 20 M fura2-AM (Invitrogen) (from a stock solution of 5 mM fura-2-AM, 20% pluronic F-127, dissolved in DMSO), plus three to four drops of antifoam A (Sigma). Trabeculae were then washed with Krebs-Henseleit solution for 15 min, and the calcium level in the bath was increased as described above. This loading protocol increased recorded muscle fluorescence to 3-5 times the autofluorescence of the unloaded muscle. When measured in two experiments, fura-2-AM loading reduced contraction force 0 -10%. Fura-2 fluorescence was measured at an emission wavelength of 510 nm, with the excitation wavelength alternated between 340 nm and 380 nm (Photon Technology International, Edison, NJ). Fluorescence signals at each wavelength were integrated at 100 points/s. Muscle autofluorescence was subtracted before the fura-2 fluorescence ratio was computed. Fura-2 ratio was measured during contractions before and intermittently during the inotropic responses. Fura-2-AM can result in nonspecific loading into multiple cell compartments (which was not determined in this study). The rapid fura-2 fluorescence transient during contraction was used as a measure of the cytosolic Ca 2ϩ transient. Inotropic responses. Cardiac ␣1-ARs were stimulated by addition of a maximal dose (10 M) of phenylephrine (PE). In wild-type mice, PE stimulates both predominant ␣1-AR subtypes on cardiac myocytes (␣1A and ␣1B). A maximal dose of the subtype-selective agonist A61603 (100 nM) was used to selectively stimulate the ␣1A-subtype. In knockout mice lacking the ␣1A-subtype (AKO), PE was used to selectively stimulate the remaining ␣1B-subtype. The ␤-AR antagonist timolol (10 M) was present in all experiments. Acute inotropic responses were assessed when contraction force stabilized, typically Ϸ20 min after agonist stimulation. For some experiments, inotropic responses were expressed using the absolute force level per unit area of myocardium (in mN/mm 2 ). For other experiments, the crosssectional area of the preparation could not be determined (e.g., due to a complex/branched trabecula structure); therefore, inotropic responses were also assessed from the developed force (systolic minus diastolic force) after addition of agonist, expressed relative to the developed force before agonist. Both measures gave similar results.
Phosphorylation status of myosin regulatory light chain. Measurements of regulatory light chain (RLC) phosphorylation in each trabecula were performed by urea/glycerol-PAGE and immunoblotting, as previously described (22) . This method separates phosphorylated RLC from nonphosphorylated RLC, allowing a direct quantitative measure of phosphorylated RLC as a fraction of total RLC. As the separation results from a single phosphate, data may also be calculated as mole of phosphate per mole RLC. After contractions were recorded, a trabecula was immediately placed in 10% ice-cold trichloroacetic acid and 10 mM dithiothreitol. The precipitated trabecula was washed free of acid with three 5-min washes in ethyl ether and resuspended by vigorous agitation in 15 l of urea sample buffer of 8 M Urea, 20 mM Tris base, 23 mM glycine, 0.2 mM EDTA, and 10 mM dithiothreitol using an orbital shaker (IKA Vibrax VXR) set at 1,400 rpm for 30 min at room temperature. Complete denaturation and solubilization was achieved by addition of urea crystals and prolonged agitation. Protein samples were centrifuged at 10,000 g for 2 min, and 5 l of supernantant fraction containing denatured proteins was A: 2 wk after bleomycin instillation, RV fractional shortening in vivo was reduced to 45% of the value before bleomycin (P ϭ 0.002). After saline instillation, RV fractional shortening in vivo was slightly reduced to ϳ80% of initial (P ϭ 0.04). B: LV in vivo fractional shortening was not affected by bleomycin or saline instillation, demonstrating the RV-specific nature of the bleomycin model. *P Ͻ 0.05; **P Ͻ 0.01; ns, not significant.
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directly loaded onto the glycerol gel system for separation of phosphorylated from nonphosphorylated RLC proteins. Briefly, polyacrylamide gels containing 40% glycerol were pre-electrophoresed for 1 h at 400 V at room temperature in a mini-gel apparatus. Reservoir buffer contained 20 mM Tris base and 23 mM glycine (pH 8.6); thioglycolate and dithiothreitol (2.3 mM each) were included in the upper reservoir. Samples were subjected to electrophoresis for 90 min at 400 V at room temperature, then transferred to a polyvinylidene difluoride membrane for 1 h at 0.3 A at 4°C. After transfer, proteins were fixed onto the polyvinylidene difluoride membrane with 0.4% glutaraldehyde/PBS for 15 min at room temperature. The membrane was then rinsed 3ϫ in PBS and immunoblotted with antibody to cardiac RLC (Enzo Life, F109 3E1). RLC was detected using ECL Plus (Pierce), and fluorescent signal acquired by Storm (GE Healthcare). RLC and p-RLC bands were auto-detected and quantified by ImageQuant TL (GE Healthcare). Statistical analysis. Data are presented as means Ϯ SE. Statistical tests (paired and unpaired t-tests, linear regression, and 2 test) were performed using Prism 6 software (GraphPad Software, La Jolla, CA) with a significance level set at P Ͻ 0.05.
RESULTS
Model of bleomycin-induced RV failure.
The RV-specific bleomycin model of RV failure was reported to cause pulmonary fibrosis, pulmonary hypertension, RV hypertrophy, decreased RV ejection fraction, and RV failure within ϳ2 wk (17) . Consistent with this we found that 2 wk after bleomycin instillation, there was a greater than twofold increase in lung weight relative to body weight, a 55% reduction in RV fractional shortening (Fig. 1A) , and high mortality (Ϸ50%). There was a 21% reduction in fractional shortening in the salinetreated group (Fig. 1A) , suggesting that instillation of saline into the lung may result in mild injury. However, the reduction in fractional shortening due to bleomycin was considerably greater than the reduction due to saline (P ϭ 0.018). With confirmation of the RV-specificity of this model, LV fractional shortening was not affected (Fig. 1B) .
Upregulation of ␣ 1 -AR inotropy in RV failure. We studied cardiac trabeculae from failing RV (bleomycin-treated) or nonfailing RV (saline-treated) and measured the acute ␣ 1 -AR inotropic response to PE, a nonselective ␣ 1 -AR agonist that stimulates both predominant ␣ 1 -AR subtypes on cardiac myocytes (␣ 1 A and ␣ 1 B). We also measured the inotropic response to the ␣ 1 A-subtype-selective agonist A61603. All experiments were in the presence of the ␤-AR blocker timolol. Figure 2 shows representative recordings of contractions of RV trabeculae with agonist stimulation. For nonfailing RV (saline treated), stimulation of the ␣ 1 A-subtype by A61603 elicited a negative inotropic effect (NIE) that was identical to that elicited by combined stimulation of both the ␣ 1 A-plus ␣ 1 B-subtypes using PE. Thus, for nonfailing RV, stimulation of the ␣ 1 A-subtype singly, or in combination with the ␣ 1 Bsubtype, elicited a NIE, consistent with our previous reports (25, 39) .
In contrast, for failing RV there was a switch to a positive inotropic effect (PIE) (Fig. 2) . This is consistent with our previous finding of increased ␣ 1 -AR inotropy in a model of RV failure induced secondary to LV failure (38) . Interestingly, the PIE elicited by A61603 (␣ 1 A agonist) was greater than the PIE elicited by PE (␣ 1 A plus ␣ 1 B mixed agonist) (discussed below).
The timing of contraction and relaxation were not affected by ␣ 1 -AR stimulation, as evidenced by the similar time course of contraction and relaxation both before and after agonist (Fig.  2B ) and from the data in Table 1 summarizing the time to peak contraction and the relaxation time.
Upregulation of ␣ 1 -AR inotropy develops 2 wk after bleomycin instillation. Figure 3A summarizes the inotropic response elicited by A61603 at various times after bleomycin instillation. For RV myocardium studied less than 2 wk after bleomycin instillation, inotropic stimulation with the ␣ 1 Asubtype agonist A61603 elicited a NIE. However, for RV trabeculae studied more than 2 wk after bleomycin, a PIE elicited by A61603 emerged. Thus the switch in the inotropic response to A61603 from a NIE in nonfailing RV to a PIE after bleomycin treatment required 2 wk to develop. Accordingly, all of the other data presented in this study involved mice more than 2 wk after bleomycin or saline instillation. Figure 3A also shows that the switch to a PIE elicited by A61603 did not occur in a subset of hearts. Nevertheless, there was a markedly increased lung weight in animals whether ␣ 1 A-subtype inotropy was increased (converter group) or not (nonconverter group) (see Table 2 ), suggesting that for some animals, the lack of upregulation of the ␣ 1 A-subtype inotropic response was not due to a lack of bleomycin-induced lung injury. Figure 3B summarizes the inotropic response elicited by A61603 for hearts studied at least 2 wk after bleomycin instillation. As described above, bleomycin-treated hearts were divided into converter or nonconverter groups based on whether A61603 elicited a PIE or NIE, respectively. Moreover, inotropic responses assessed using absolute force units (Fig.  3B) were consistent with inotropic responses assessed using relative force units.
Upregulation of ␣ 1 -AR inotropy in failing RV requires the ␣ 1 A-subtype. Figure 4 summarizes the contractile response to stimulation of the ␣ 1 A-subtype singly by A61603 or in combination with the ␣ 1 B-subtype using PE. For nonfailing RV, both A61603 and PE elicited a NIE (Fig. 4A) and there was no statistical difference between the responses to these agonists. After bleomycin treatment, Ϸ60% of animals had a markedly increased ␣ 1 A-subtype inotropic response than saline-treated controls (converter group, Fig. 4C ). For the remainder, the ␣ 1 A-subtype inotropic response was similar to nonfailing RV myocardium (nonconverter group, Fig. 4B ). For RV myocardium from bleomycin-treated animals, the nonconverter group was similar to the nonfailing RV group in having a NIE elicited both by A61603 or PE (Fig. 4B) . In contrast, for the converter group, after 2 wk of bleomycin treatment, there was a switch in the ␣ 1 A-subtype inotropic response to a PIE (Fig. 4C ). As noted in Fig. 2 , the pooled data in Fig. 4C show that the PIE elicited by the ␣ 1 A-subtype agonist A61603 was appreciably greater than that induced by combined stimulation of both ␣ 1 A-and ␣ 1 B-subtypes with PE. The difference between the inotropic response to A61603 (reflecting the ␣ 1 A-subtype) versus the inotropic response to PE (reflecting ␣ 1 A-plus ␣ 1 B-subtypes) may reflect the inotropic effect mediated by the ␣ 1 B-subtype alone. The difference between the inotropic response to A61603 minus the response to PE is calculated to be a NIE attributed to the ␣ 1 B-subtype (Fig. 4C) .
Taken together, these data suggest that the ␣ 1 A-subtype mediates a NIE in nonfailing RV, but in failing RV the ␣ 1 A-subtype inotropic response can be switched to a PIE. In contrast, the ␣ 1 B-subtype mediates an NIE in nonfailing RV, and the ␣ 1 B-subtype response is not switched in failing RV. Thus upregulation of ␣ 1 -AR inotropy in the failing RV in- Values are means Ϯ SE. Measurements of the time to peak force (interval from the start of a contraction to the peak contraction force) and 50% relaxation time (RT50, interval from the peak contraction force to the time when force had relaxed by 50%) are shown. Nonfailing or failing right ventricle (RV) myocardium was obtained from animals 2 wk after a single tracheal instillation of saline or bleomycin, respectively. For these experiments, ␣1-adrenergic receptor (␣1-AR) stimulation elicited a negative inotropic response in nonfailing RV, but a positive inotropic response in failing RV. However, the timing of contraction and relaxation was not statistically different than before agonist (number/group indicated in parentheses). PE, phenylephrine. Fig. 3 . Upregulation of ␣1-AR inotropy 2 wk after bleomycin instillation. A: summary of the positive inotropic () and negative inotropic responses (OE) elicited by the ␣1A-subtype agonist A61603 (A1603) for different samples of RV myocardium from different animals and for various times after a single bleomycin instillation or with biweekly bleomycin instillation (OE). Positive inotropic responses were observed 14 days after initial bleomycin administration. B: summary of inotropic responses to A61603: absolute levels of developed force before (basal) and after addition of A61603. Data from failing RV are divided into nonconverter or converter groups, depending on whether A61603 elicited a negative inotropic effect (NIE) or positive inotropic effect (PIE). **P Ͻ 0.01; n ϭ 6 -8/group. volves functional antagonism between the ␣ 1 -AR subtypes, with a PIE mediated solely by the ␣ 1 A-subtype and antagonized by a NIE mediated by the ␣ 1 B-subtype.
To confirm the key role of the ␣ 1 A-subtype in upregulation of ␣ 1 -AR inotropy in the failing RV, we used knockout mice lacking the ␣ 1 A-subtype (AKO). For AKO mice, the predominant remaining ␣ 1 -AR subtype on cardiac myocytes is the ␣ 1 B-subtype. Therefore, inotropic stimulation of myocardium from AKO mice using PE would stimulate the remaining ␣ 1 B-subtype. Figure 5 shows original records of the contractile response of AKO myocardium following stimulation with A61603 or PE. As expected, RV myocardium from AKO mice was unresponsive to the ␣ 1 A-subtype-selective agonist A61603. For mice 2 wk after tracheal instillation of saline or bleomycin, there was a NIE elicited by PE. The summary of all data (Fig. 6) shows that for AKO myocardium, stimulation of the remaining ␣ 1 B-subtype using PE resulted in a NIE (force decreased Ϸ50%) in both nonfailing RV myocardium (Fig. 6A ) and failing RV myocardium (Fig. 6B) . Figure 6B shows that a NIE elicited by PE was observed for all AKO mice that had been instilled with bleomycin. Thus, for RV myocardium from animals instilled with bleomycin, a PIE in response to PE was observed for most wild-type hearts but not observed for AKO hearts. This difference is statistically significant (P Ͻ 0.05, 2 test). We conclude that the ␣ 1 B-subtype elicits a NIE, in both nonfailing and failing RV. This is consistent with the data in Fig. 4 suggesting the ␣ 1 B-subtype has an NIE in both nonfailing and failing RV. Thus upregulation of ␣ 1 -AR inotropy in the failing RV requires the ␣ 1 A-subtype. Moreover, in failing RV, the ␣ 1 B-subtype does not switch to a PIE but elicits a NIE. Together these data suggest that in the failing RV functional antagonism can emerge between the ␣ 1 A-subtype (that mediates a PIE) and the ␣ 1 B-subtype (that mediates an NIE). Specifically, when the ␣1A-subtype is stimulated in combination with the ␣ 1 B-subtype the inotropic response is lower than when the ␣ 1 A-subtype is stimulated in the absence of the ␣ 1 B-subtype.
Mechanisms involved in the switch in ␣ 1 A-subtype inotropy in failing RV. The PIE elicited by ␣ 1 -ARs was suggested to involve increased Ca 2ϩ mobilization (5). We determined the effect of ␣ 1 -AR inotropic stimulation on the fura-2 Ca 2ϩ transient. A NIE elicited by ␣ 1 A-subtype stimulation in nonfailing RV was associated with a reduction of the Ca 2ϩ transient (Fig. 7A) . In contrast, a PIE elicited by the ␣ 1 Asubtype in failing RV was associated with an increase of the Ca 2ϩ transient. Figure 7B summarizes that there was a significant positive relationship between changes in the Ca 2ϩ transient and changes in contraction. This suggests that ␣ 1 Asubtype-mediated effects on Ca 2ϩ handling is a determinant of the contractile response and that an increased Ca 2ϩ transient amplitude contributed to upregulation of ␣ 1 A-subtype inotropic responses in the failing RV.
The PIE elicited by ␣ 1 -ARs was also previously suggested to involve increased phosphorylation of myosin RLC, which leads to increased myofilament Ca 2ϩ -sensitivity (2). Therefore, for trabeculae that manifested a PIE elicited by A61603, we measured the extent of phosphorylation of cardiac RLC. Figure 8 shows that for nonfailing RV myocardium, the RLC phosphorylation level was ϳ50% as previously reported for contracting Values are means Ϯ SE. A single instillation of bleomycin (0.075 U) or saline was given. After at least 2 wk, the effect of bleomycin was assessed on lung weight and on the RV free wall weight. Bleomycin resulted in a decrease in body weight, an increase in lung weight, and increased RV weight. The bleomycin group is divided into 2 subgroups, depending on whether the ␣1A-subtype inotropic response was switched to a positive inotropic response (converter) or remained a negative inotropic response (nonconverter) (number/group indicated in parentheses). ****Significantly different than vehicle (P Ͻ 0.0001); §Significantly different that nonconverter (P Ͻ 0.05). Fig. 4 . Upregulation of ␣1-AR inotropy in failing RV mediated by the ␣1A-subtype. Summary of inotropic responses to maximal stimulation of the ␣1A-subtype either singly using A61603 or in combination with the ␣1B-subtype using PE are shown. Animals were studied Ͼ14 days after a single instillation of saline (nonfailing RV) or bleomycin (failing RV). Some animals received biweekly bleomycin instillation (triangles). Individual experimental values are shown, and the pooled means and SE indicated. A: for nonfailing RV, both A61603 and PE elicited a similar NIE. B: after bleomycin instillation, for a subset of animals (nonconverter group), A61603 and PE continued to elicit a NIE. C: in contrast, for some animals there was a conversion to a PIE mediated by A61603 (converter group). The PIE mediated by A61603 was greater than that mediated by PE (P ϭ 0.0173). The difference between the response to A61603 minus the response to PE may reflect a NIE mediated by the ␣1B-subtype. *P Ͻ 0.05. myocardium (10) . Moreover, the RLC phosphorylation level was not changed by A61603 stimulation. This indicates that the NIE elicited by ␣ 1 A-subtype stimulation in nonfailing RV did not involve decreased RLC phosphorylation, but instead, other mechanisms such as decreased Ca 2ϩ transients may be important. Interestingly, the RLC phosphorylation level for the failing RV (Ϸ15% of total RLC) was substantially lower than nonfailing RV (Ϸ40% of total RLC, P ϭ 0.03). Moreover, for hearts that manifested a PIE in response to ␣ 1 A-subtype stimulation, there was a marked increase in the level of RLC phosphorylation (P ϭ 0.036). Thus increased RLC phosphorylation may contribute to the PIE elicited by the ␣ 1 A-subtype in the failing RV.
DISCUSSION
RV failure results in downregulation of ␤-ARs in humans and multiple experimental models in rodents (30) . In contrast, ␣ 1 -AR inotropic responses are upregulated in failing RV (38) . Of the two predominant subtypes of ␣ 1 -AR on cardiac myocytes (␣ 1 A and ␣ 1 B), the current study indicates that upregulation of ␣ 1 -AR inotropy in failing RV myocardium is mediated solely by the ␣ 1 A-subtype. An increased level of contraction mediated by the ␣ 1 A-subtype might provide inotropic support for the failing RV. Moreover, the ␣ 1 A-subtype may represent a novel therapeutic target to augment the function of the failing RV. Because the prognosis of heart failure patients with pulmonary hypertension is strongly related to RV dysfunction (14) , strategies to improve RV function may be beneficial for improving survival of patients with severe RV failure.
␣ 1 -AR signaling in heart failure. It has been generally believed that ␣ 1 -ARs, along with all G protein-coupled receptors that signal through G␣q, play a pathogenic role in heart failure. In contrast, this view has been challenged by the suggestion that ␣ 1 -AR signaling is beneficial in heart failure (3, 20, 29) . Consistent with ␣ 1 -ARs mediating a cardioprotective effect, knockout of ␣ 1 -ARs prevents normal cardiac growth (28) and worsens cardiomyopathy after pressure overload (27) . Furthermore, a large clinical trial (ALLHAT) of an ␣ 1 -AR antagonist was stopped prematurely because of an increase in heart failure in the ␣ 1 -AR antagonist-treated group (1). These findings suggest that a higher level of ␣ 1 -AR activation is cardioprotective in heart failure. Consistent with this, in human heart failure, where ␤-ARs are downregulated, ␣ 1 -AR mediated inotropy can equal ␤-AR mediated inotropy, raising the possibility that a relative increase in ␣ 1 -AR inotropy has a beneficial effect (34) . In the context of the RV, we find that ␣ 1 -AR inotropic responses are upregulated in the failing RV (38) , which might help the failing RV adapt to increased pulmonary pressures.
Cardioprotective role of ␣ 1 A-subtype signaling. Previous studies suggest that ␣ 1 A-subtype signaling has cardioprotective effects. ␣ 1 A-subtype overexpression enhances contractility without causing hypertrophy (23), protects against pressureoverload-induced dysfunction (11), limits postinfarct cardiomyopathy (12) , and protects against ischemic injury (32) . Recent studies found that the ␣ 1 A-subtype mediates a prosurvival effect in cardiac myocytes subjected to multiple pathological conditions (18) . Furthermore, ␣ 1 A-subtype agonist treatment prevents apoptosis in a heart failure model in vivo (6) and prevents cell death and fibrosis and improves in vivo function and survival in multiple heart failure models (26) . Consistent with beneficial effects mediated by the ␣ 1 A-subtype, in the present study we found that the ␣ 1 A-subtype, but not the ␣ 1 B-subtype, mediated increased myocardial contraction in the failing RV.
Functional antagonism between ␣ 1 -AR subtypes in failing RV. We found that for nonfailing RV, the ␣ 1 A-and ␣ 1 Bsubtypes both elicited a NIE of similar magnitude when stimulated singly or in combination, consistent with our previous study (25) . Nevertheless, in failing RV we found upregulation of ␣ 1 -AR inotropy and the emergence of functional antagonism AKO failing RV Fig. 6 . Negative inotropy mediated by the ␣1B-subtype. A and B: summary of data from all AKO experiments. RV myocardium from AKO mice did not respond to A61603. For AKO mice, stimulation of the remaining ␣1B-subtype using PE elicited a NIE in all experiments involving nonfailing RV or failing RV. Thus the ␣1B-subtype mediates a NIE in both nonfailing and failing RV. *P Ͻ 0.05; ***P Ͻ 0.001. between ␣ 1 A-and ␣ 1 B-subtypes. In the failing RV, the ␣ 1 Asubtype inotropic response was switched from a NIE to a PIE in Ϸ60% of hearts. However, the inotropic response mediated by the ␣ 1 B-subtype was not observed to be switched and remained as a NIE in both nonfailing and failing RV. Therefore, for the failing RV, the inotropic response to nonsubtype selective ␣ 1 -AR stimulation might be complex and consist of stimulatory effects mediated by the ␣ 1 A-subtype that are antagonized by inhibitory effects mediated by the ␣ 1 B-subtype.
Our findings are consistent with previous studies that suggested that the two predominant cardiac ␣ 1 -AR subtypes can mediate different inotropic responses in LV myocardium. Previously, the ␣ 1 A-subtype was linked to a PIE (23) , and the ␣ 1 B-subtype linked to a NIE (16, 33) . Furthermore, in rat myocardium, stimulation of the ␣ 1 A-subtype causes increases of contractions, Ca 2ϩ transients, myofilament response to Ca 2ϩ , and intracellular pH (13); however, ␣ 1 B-subtype stimulation decreases contractions, Ca 2ϩ transients, and pH (13) . Mechanisms contributing to upregulated ␣ 1 A-subtype response in the failing RV. In general, our finding that the ␣ 1 A-subtype elicits a NIE in nonfailing RV but a PIE in failing RV suggests that the signaling pathways linking ␣ 1 A-subtype receptors to the cellular effectors can be altered in disease.
In the nonfailing RV, stimulation of the ␣ 1 A-subtype mediated a decrease in both the Ca 2ϩ transient and contraction. This is consistent with our previous studies suggesting a decrease in the amplitude of the Ca 2ϩ transient contributed to a NIE elicited by ␣ 1 -ARs (5, 25) . In contrast, in the failing RV, ␣ 1 A-subtype stimulation resulted in an increase in the Ca 2ϩ transient and a PIE. This suggests that a switch in the effect of ␣ 1 A-subtype stimulation on Ca 2ϩ handling, from inhibitory in nonfailing RV to stimulatory in failing RV, contributed to the switch in the inotropic response from a NIE in nonfailing RV to a PIE in failing RV.
Previous studies suggest that phosphorylation of myosin RLC mediates increased myofilament Ca 2ϩ sensitivity and contributes to a PIE mediated by ␣ 1 -ARs (2, 38, 39) . Consistent with this, in the present study we found that in failing RV, the PIE elicited by ␣ 1 A-subtype stimulation was associated with increased cardiac RLC phosphorylation.
Heterogeneity of ␣ 1 -AR inotropy after bleomycin treatment. Previously, we found there was upregulation of ␣ 1 -AR inotropy in a model of RV failure that was induced secondary to LV failure following myocardial infarction (MI) of the LV (38) . However, for hearts subjected to small infarcts we found that the ␣ 1 -AR inotropic response of RV myocardium was not upregulated, suggesting the existence of an injury threshold for switching of the RV ␣ 1 -AR inotropic response in heart failure to a PIE (38) .
Consistent with our previous study, in the present study, a switch to a PIE elicited by ␣ 1 -ARs was not observed in all experiments. The duration of RV injury may be a determinant transients after A61603 were expressed relative to their pre-agonist amplitude (defined as 100%). For all experiments involving myocardium from hearts at least 2 wk after bleomycin or saline instillation into the trachea, following ␣1A-subtype stimulation, there was a significant positive linear relationship between changes in the amplitude of the Ca 2ϩ transient and changes in the amplitude of contraction (R 2 ϭ 0.787, P Ͻ 0.0001) (the relationship remained significant after excluding the most positive value). Some animals received biweekly bleomycin instillation (triangles).
of upregulation of ␣ 1 -AR inotropy as evidenced by the finding that a PIE elicited by ␣ 1 -ARs was not observed before 2 wk after bleomycin instillation. Interestingly, the RV injury model of bleomycin-induced pulmonary fibrosis is associated with a high level of mortality within the first 2 wk after bleomycin instillation (17) , and before upregulation of ␣ 1 -AR inotropy develops. Potentially, upregulation of ␣ 1 -AR inotropy may be protective and contribute to a lower mortality in the period beyond 2 wk after bleomycin instillation.
There was greater RV hypertrophy in hearts that did manifest a switch to a PIE elicited by ␣ 1 -ARs (Table 2) . Potentially, both the increased inotropic response and the greater RV mass might contribute to a beneficial effect on RV function.
Limitations. The current study found upregulation of myocardial ␣ 1 A-subtype inotropic responses using cardiac trabeculae studied in vitro. Further study is warranted to search for a functional in vivo correlate. The current study used cardiac trabeculae under in vitro conditions of low temperature and low pacing rate. The level of absolute force development observed was considerably lower than that of previous studies using more physiological conditions (35, 36) .
The current study was performed using mouse myocardium. Although, ␣ 1 -AR levels and regulation in mouse myocardium are similar to those in human (19, 21) , future studies should determine whether ␣ 1 A-subtype signaling is upregulated in RV myocardium from human hearts with RV failure. Further study is needed to determine the significance of our finding upregulation of ␣ 1 A-subtype inotropy in the failing RV. In this regard, chronic agonist stimulation of the ␣ 1 A-subtype may be beneficial in the failing heart (6, 26) , and upregulation of ␣ 1 Asubtype function in the failing RV may contribute to a beneficial effect. Finally, the mechanisms mediating upregulation of ␣ 1 A-subtype inotropy remain unclear. For example, the roles of changes in RLC phosphorylation and Ca 2ϩ transients were not resolved in this study. Moreover, the underlying mechanisms by which the ␣ 1 A-subtype mediates a decreased Ca 2ϩ transient in nonfailing RV but an increased Ca 2ϩ transient in failing RV need to be defined.
Conclusion
In conclusion, the upregulated ␣ 1 -AR inotropic response of failing RV is mediated by the ␣ 1 A-subtype and not the ␣ 1 Bsubtype. The ␣ 1 A-subtype may represent a novel therapeutic target to augment the function of the failing RV. Immunoblots and quantitative summary of RLC phosphorylation, with or without acute stimulation with A61603 for nonfailing RV and failing RV myocardium that had a positive inotropic response to A61603, are shown. In failing RV, RLC phosphorylation was reduced versus nonfailing RV. In failing RV, RLC phosphorylation was increased by ␣1A-subtype stimulation.
